YD Bio (YDESW) Assets Average (2025 - 2026)
YD Bio's (YDESW) quarterly Assets Average came in at $11.9 million in Q2 2026, up 87.64% year-over-year from $6.4 million in Q2 2025, and up 21.5% quarter-over-quarter from $9.8 million in Q4 2025.
Powered by 
Analysis
YD Bio (YDESW) Assets Average (2025 - 2026) Analysis & Trends
YD Bio (YDESW) has reported Assets Average for 2 consecutive years, with $11.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Assets Average rose 87.64% year-over-year to $11.9 million in Q2 2026; TTM through Jun 2026 was $11.9 million, a 87.64% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, changed N/A from the prior year.
- Assets Average was $11.9 million for Q2 2026 at YD Bio, up from $9.8 million in the prior quarter.
- Over five years, Assets Average peaked at $11.9 million in Q2 2026 and troughed at $6.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn | 5.51 Bn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - | 11.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.92 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Jun 30, 2025 | 6.35 Mn |